<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:52:19 -0700</creation_date>
  <update_date>2013-05-27 11:21:04 -0600</update_date>
  <accession>HMDBP00910</accession>
  <secondary_accessions>
    <accession>6198</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>HMG-CoA reductase</synonym>
  </synonyms>
  <gene_name>HMGCR</gene_name>
  <general_function>Involved in hydroxymethylglutaryl-CoA reductase (NADPH) activity</general_function>
  <specific_function>Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins.
</specific_function>
  <pathways>
    <pathway>
      <name>(R)-mevalonate biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>Terpenoid backbone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00900</kegg_map_id>
    </pathway>
    <pathway>
      <name>Bile secretion</name>
      <smpdb_id/>
      <kegg_map_id>map04976</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00227</accession>
      <name>Mevalonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01375</accession>
      <name>3-Hydroxy-3-methylglutaryl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00217</accession>
      <name>NADP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00221</accession>
      <name>NADPH</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01423</accession>
      <name>Coenzyme A</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05022</accession>
      <name>Pravastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05007</accession>
      <name>Simvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05006</accession>
      <name>Atorvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14372</accession>
      <name>Lovastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14037</accession>
      <name>6-Hydroxyfluvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15230</accession>
      <name>Rosuvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB59629</accession>
      <name>(R)-mevalonate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB59597</accession>
      <name>Hydrogen Ion</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>hydroxymethylglutaryl-coa reductase (nadph) activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nadp or nadph binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cofactor binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>coenzyme binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on ch-oh group of donors</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on the ch-oh group of donors, nad or nadp as acceptor</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>primary metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>lipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular lipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>isoprenoid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>isoprenoid biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cofactor metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>coenzyme metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>coenzyme a metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>organelle membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>peroxisomal membrane</description>
      <go_id>GO:0005778</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>hydroxymethylglutaryl-CoA reductase (NADPH) activity</description>
      <go_id>GO:0004420</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>hydroxymethylglutaryl-CoA reductase activity</description>
      <go_id>GO:0042282</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>NADPH binding</description>
      <go_id>GO:0070402</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>aging</description>
      <go_id>GO:0007568</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular lipid metabolic process</description>
      <go_id>GO:0044255</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cholesterol biosynthetic process</description>
      <go_id>GO:0006695</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>coenzyme A metabolic process</description>
      <go_id>GO:0015936</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>embryo development</description>
      <go_id>GO:0009790</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>isoprenoid biosynthetic process</description>
      <go_id>GO:0008299</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of MAP kinase activity</description>
      <go_id>GO:0043407</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of skeletal muscle tissue development</description>
      <go_id>GO:0048643</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>protein tetramerization</description>
      <go_id>GO:0051262</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to nutrient</description>
      <go_id>GO:0007584</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>visual learning</description>
      <go_id>GO:0008542</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Peroxisome membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>5</chromosome_location>
    <locus>5q13.3-q14</locus>
    <gene_sequence>&gt;2667 bp
ATGTTGTCAAGACTTTTTCGAATGCATGGCCTCTTTGTGGCCTCCCATCCCTGGGAAGTC
ATAGTGGGGACAGTGACACTGACCATCTGCATGATGTCCATGAACATGTTTACTGGTAAC
AATAAGATCTGTGGTTGGAATTATGAATGTCCAAAGTTTGAAGAGGATGTTTTGAGCAGT
GACATTATAATTCTGACAATAACACGATGCATAGCCATCCTGTATATTTACTTCCAGTTC
CAGAATTTACGTCAACTTGGATCAAAATATATTTTGGGTATTGCTGGCCTTTTCACAATT
TTCTCAAGTTTTGTATTCAGTACAGTTGTCATTCACTTCTTAGACAAAGAATTGACAGGC
TTGAATGAAGCTTTGCCCTTTTTCCTACTTTTGATTGACCTTTCCAGAGCAAGCACATTA
GCAAAGTTTGCCCTCAGTTCCAACTCACAGGATGAAGTAAGGGAAAATATTGCTCGTGGA
ATGGCAATTTTAGGTCCTACGTTTACCCTCGATGCTCTTGTTGAATGTCTTGTGATTGGA
GTTGGTACCATGTCAGGGGTACGTCAGCTTGAAATTATGTGCTGCTTTGGCTGCATGTCA
GTTCTTGCCAACTACTTCGTGTTCATGACTTTCTTCCCAGCTTGTGTGTCCTTGGTATTA
GAGCTTTCTCGGGAAAGCCGCGAGGGTCGTCCAATTTGGCAGCTCAGCCATTTTGCCCGA
GTTTTAGAAGAAGAAGAAAATAAGCCGAATCCTGTAACTCAGAGGGTCAAGATGATTATG
TCTCTAGGCTTGGTTCTTGTTCATGCTCACAGTCGCTGGATAGCTGATCCTTCTCCTCAA
AACAGTACAGCAGATACTTCTAAGGTTTCATTAGGACTGGATGAAAATGTGTCCAAGAGA
ATTGAACCAAGTGTTTCCCTCTGGCAGTTTTATCTCTCTAAAATGATCAGCATGGATATT
GAACAAGTTATTACCCTAAGTTTAGCTCTCCTTCTGGCTGTCAAGTACATCTTCTTTGAA
CAAACAGAGACAGAATCTACACTCTCATTAAAAAACCCTATCACATCTCCTGTAGTGACA
CAAAAGAAAGTCCCAGACAATTGTTGTAGACGTGAACCTATGCTGGTCAGAAATAACCAG
AAATGTGATTCAGTAGAGGAAGAGACAGGGATAAACCGAGAAAGAAAAGTTGAGGTTATA
AAACCCTTAGTGGCTGAAACAGATACCCCAAACAGAGCTACATTTGTGGTTGGTAACTCC
TCCTTACTCGATACTTCATCAGTACTGGTGACACAGGAACCTGAAATTGAACTTCCCAGG
GAACCTCGGCCTAATGAAGAATGTCTACAGATACTTGGGAATGCAGAGAAAGGTGCAAAA
TTCCTTAGTGATGCTGAGATCATCCAGTTAGTCAATGCTAAGCATATCCCAGCCTACAAG
TTGGAAACTCTGATGGAAACTCATGAGCGTGGTGTATCTATTCGCCGACAGTTACTTTCC
AAGAAGCTTTCAGAACCTTCTTCTCTCCAGTACCTACCTTACAGGGATTATAATTACTCC
TTGGTGATGGGAGCTTGTTGTGAGAATGTTATTGGATATATGCCCATCCCTGTTGGAGTG
GCAGGACCCCTTTGCTTAGATGAAAAAGAATTTCAGGTTCCAATGGCAACAACAGAAGGT
TGTCTTGTGGCCAGCACCAATAGAGGCTGCAGAGCAATAGGTCTTGGTGGAGGTGCCAGC
AGCCGAGTCCTTGCAGATGGGATGACTCGTGGCCCAGTTGTGCGTCTTCCACGTGCTTGT
GACTCTGCAGAAGTGAAAGCCTGGCTCGAAACATCTGAAGGGTTCGCAGTGATAAAGGAG
GCATTTGACAGCACTAGCAGATTTGCACGTCTACAGAAACTTCATACAAGTATAGCTGGA
CGCAACCTTTATATCCGTTTCCAGTCCAGGTCAGGGGATGCCATGGGGATGAACATGATT
TCAAAGGGTACAGAGAAAGCACTTTCAAAACTTCACGAGTATTTCCCTGAAATGCAGATT
CTAGCCGTTAGTGGTAACTATTGTACTGACAAGAAACCTGCTGCTATAAATTGGATAGAG
GGAAGAGGAAAATCTGTTGTTTGTGAAGCTGTCATTCCAGCCAAGGTTGTCAGAGAAGTA
TTAAAGACTACCACAGAGGCTATGATTGAGGTCAACATTAACAAGAATTTAGTGGGCTCT
GCCATGGCTGGGAGCATAGGAGGCTACAACGCCCATGCAGCAAACATTGTCACCGCCATC
TACATTGCCTGTGGACAGGATGCAGCACAGAATGTTGGTAGTTCAAACTGTATTACTTTA
ATGGAAGCAAGTGGTCCCACAAATGAAGATTTATATATCAGCTGCACCATGCCATCTATA
GAGATAGGAACGGTGGGTGGTGGGACCAACCTACTACCTCAGCAAGCCTGTTTGCAGATG
CTAGGTGTTCAAGGAGCATGCAAAGATAATCCTGGGGAAAATGCCCGGCAGCTTGCCCGA
ATTGTGTGTGGGACCGTAATGGCTGGGGAATTGTCACTTATGGCAGCATTGGCAGCAGGA
CATCTTGTCAAAAGTCACATGATTCACAACAGGTCGAAGATCAATTTACAAGACCTCCAA
GGAGCTTGCACCAAGAAGACAGCCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>888</residue_number>
    <molecular_weight>97475.155</molecular_weight>
    <theoretical_pi>6.735</theoretical_pi>
    <pfams>
      <pfam>
        <name>HMG-CoA_red</name>
        <pfam_id>PF00368</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;3-hydroxy-3-methylglutaryl-coenzyme A reductase
MLSRLFRMHGLFVASHPWEVIVGTVTLTICMMSMNMFTGNNKICGWNYECPKFEEDVLSS
DIIILTITRCIAILYIYFQFQNLRQLGSKYILGIAGLFTIFSSFVFSTVVIHFLDKELTG
LNEALPFFLLLIDLSRASTLAKFALSSNSQDEVRENIARGMAILGPTFTLDALVECLVIG
VGTMSGVRQLEIMCCFGCMSVLANYFVFMTFFPACVSLVLELSRESREGRPIWQLSHFAR
VLEEEENKPNPVTQRVKMIMSLGLVLVHAHSRWIADPSPQNSTADTSKVSLGLDENVSKR
IEPSVSLWQFYLSKMISMDIEQVITLSLALLLAVKYIFFEQTETESTLSLKNPITSPVVT
QKKVPDNCCRREPMLVRNNQKCDSVEEETGINRERKVEVIKPLVAETDTPNRATFVVGNS
SLLDTSSVLVTQEPEIELPREPRPNEECLQILGNAEKGAKFLSDAEIIQLVNAKHIPAYK
LETLMETHERGVSIRRQLLSKKLSEPSSLQYLPYRDYNYSLVMGACCENVIGYMPIPVGV
AGPLCLDEKEFQVPMATTEGCLVASTNRGCRAIGLGGGASSRVLADGMTRGPVVRLPRAC
DSAEVKAWLETSEGFAVIKEAFDSTSRFARLQKLHTSIAGRNLYIRFQSRSGDAMGMNMI
SKGTEKALSKLHEYFPEMQILAVSGNYCTDKKPAAINWIEGRGKSVVCEAVIPAKVVREV
LKTTTEAMIEVNINKNLVGSAMAGSIGGYNAHAANIVTAIYIACGQDAAQNVGSSNCITL
MEASGPTNEDLYISCTMPSIEIGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLAR
IVCGTVMAGELSLMAALAAGHLVKSHMIHNRSKINLQDLQGACTKKTA</protein_sequence>
  </protein_properties>
  <genbank_protein_id>306865</genbank_protein_id>
  <uniprot_id>P04035</uniprot_id>
  <uniprot_name>HMDH_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1DQ8</pdb_id>
    <pdb_id>1DQ9</pdb_id>
    <pdb_id>1DQA</pdb_id>
    <pdb_id>1HW8</pdb_id>
    <pdb_id>1HW9</pdb_id>
    <pdb_id>1HWI</pdb_id>
    <pdb_id>1HWJ</pdb_id>
    <pdb_id>1HWK</pdb_id>
    <pdb_id>1HWL</pdb_id>
    <pdb_id>2Q1L</pdb_id>
    <pdb_id>2Q6B</pdb_id>
    <pdb_id>2Q6C</pdb_id>
    <pdb_id>2R4F</pdb_id>
    <pdb_id>3BGL</pdb_id>
    <pdb_id>3CCT</pdb_id>
    <pdb_id>3CCW</pdb_id>
    <pdb_id>3CCZ</pdb_id>
    <pdb_id>3CD0</pdb_id>
    <pdb_id>3CD5</pdb_id>
    <pdb_id>3CD7</pdb_id>
    <pdb_id>3CDA</pdb_id>
    <pdb_id>3CDB</pdb_id>
  </pdb_ids>
  <genbank_gene_id>M11058</genbank_gene_id>
  <genecard_id>HMGCR</genecard_id>
  <geneatlas_id>HMGCR</geneatlas_id>
  <hgnc_id>HGNC:5006</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Luskey KL, Stevens B: Human 3-hydroxy-3-methylglutaryl coenzyme A reductase. Conserved domains responsible for catalytic activity and sterol-regulated degradation. J Biol Chem. 1985 Aug 25;260(18):10271-7.</reference_text>
      <pubmed_id>2991281</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J: Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J. 2000 Mar 1;19(5):819-30.</reference_text>
      <pubmed_id>10698924</pubmed_id>
    </reference>
    <reference>
      <reference_text>Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase.  Science. 2001 May 11;292(5519):1160-4.</reference_text>
      <pubmed_id>11349148</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.</reference_text>
      <pubmed_id>10391209</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Abe Y, Suzuki T, Ono C, Iwamoto K, Hosobuchi M, Yoshikawa H: Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum. Mol Genet Genomics. 2002 Jul;267(5):636-46. Epub 2002 Jun 28.</reference_text>
        <pubmed_id>12172803</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Miyazaki A, Koieyama T, Shimada Y, Kikuchi T, Nezu H, Ito K, Kasanuki N, Koga T: Effects of pravastatin sodium on mevalonate metabolism in common marmosets.  J Biochem. 2002 Sep;132(3):395-400.</reference_text>
        <pubmed_id>12204108</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Buxbaum JD, Geoghagen NS, Friedhoff LT: Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alzheimers Dis. 2001 Apr;3(2):221-229.</reference_text>
        <pubmed_id>12214063</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Baranova NA, Kreier VG, Egorov NS: [Concentration on Diapak C 16 capsules of lovastatin, mevinolinic acid and other inhibitors of biosynthesis of sterins produced by Penicillium citrinum 89]. Antibiot Khimioter. 2002;47(4):3-6.</reference_text>
        <pubmed_id>12369143</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Farina HG, Bublik DR, Alonso DF, Gomez DE: Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis. 2002;19(6):551-9.</reference_text>
        <pubmed_id>12405293</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC: Emerging therapies for multiple myeloma.  Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.</reference_text>
        <pubmed_id>19249983</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S: Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.</reference_text>
        <pubmed_id>12082550</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC: Emerging therapies for multiple myeloma.  Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.</reference_text>
        <pubmed_id>19249983</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>Carbonell T, Freire E: Binding thermodynamics of statins to HMG-CoA reductase.  Biochemistry. 2005 Sep 6;44(35):11741-8.</reference_text>
        <pubmed_id>16128575</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>Chapman MJ, Caslake M, Packard C, McTaggart F: New dimension of statin action on ApoB atherogenicity.  Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.</reference_text>
        <pubmed_id>12539816</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>Davidson MH: Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Jan;11(1):125-41.</reference_text>
        <pubmed_id>11772327</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>Hanefeld M: Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor.  Int J Clin Pract. 2001 Jul-Aug;55(6):399-405.</reference_text>
        <pubmed_id>11501230</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>Holdgate GA, Ward WH, McTaggart F: Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans. 2003 Jun;31(Pt 3):528-31.</reference_text>
        <pubmed_id>12773150</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M: Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001 Mar 8;87(5A):28B-32B.</reference_text>
        <pubmed_id>11256847</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>Olsson AG, McTaggart F, Raza A: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.  Cardiovasc Drug Rev. 2002 Winter;20(4):303-28.</reference_text>
        <pubmed_id>12481202</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
